时迈药业
  • About us
    Company overview our culture milestones leadership contact US
  • Science & Pipeline
    Technology platform pipeline
  • partnering
    Partners partnering strategy
  • Join us
  • News
CN
  • EN
    CN
  • Home
  • about us
    Company overview our culture milestones leadership contact US
  • Science & Pipeline
    Technology platform pipeline
  • partnering
    Partners partnering strategy
  • Join us
  • News
  • Join us
网站地图
Home
Home
About Us
Company overview
our culture
milestones
leadership
contact US
Science & Pipeline
Technology platform
pipeline
partnering
Partners
partnering strategy
News
  • Company news
    Shimai Pharma Presents DNV3 (LAG-3 Antibody) Combination Therapy Results for Melanoma at ASCO 2025 Annual Meeting Shimai Pharma Presents SMET12 (EGFR×CD3 Bispecific Antibody) Combination Therapy Results for Advanced NSCLC at ASCO 2025 Annual Meeting International Endorsement, Global Leadership | GPC3×CD3 Bispecific Antibody CMD011 Receives FDA IND Clearance
  • science highlights
Join Us
join us
时迈药业
CHINA
U.S.A
  • 时迈药业
    Address:2008 Huachuang Edifice, Jianye RD No.511, Binjiang, Hangzhou
    时迈药业
    Tel:+0571-87314597
    时迈药业
    Mail : HR@centrymed.com
    时迈药业
    时迈药业
  • 时迈药业
    Address:5107 Pegasus Court, Suite L Frederick, MD 21704, U.S.A
    时迈药业
    Tel:+0571-87314597
    时迈药业
    Mail : HR@centrymed.com
    时迈药业
    时迈药业
  • about us
    Company overview our culture milestones leadership contact US
  • Science & Pipeline
    Technology platform pipeline
  • partnering
    Partners partnering strategy
  • News
  • Join us
ICP NO.18020885-1
|
33010802013098
Copyright2025 Zhejiang Shimai Pharmaceutical Co.,Ltd DESIGNBY:5ISJ.COM
Sitemap
Powered By : HANSUN
时迈药业
: mailbox
时迈药业
: Office System